ChristopherWalterRyanMD

Oncology • Portland, OR

Professor of Medicine, Oregon Health and Science University, Knight Cancer Institute

Join to view full profile

Dr. Ryan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ryan's full profile

Already have an account?

Office
3303 Sw Bond Ave
7th Floor
Portland, OR 97239
Phone+1 503-494-6594

Education & Training

University of ChicagoFellowship, Hematology and Medical Oncology, 1997 - 2000
University of ChicagoResidency, Internal Medicine, 1994 - 1997
SUNY Upstate Medical UniversityClass of 1994

Certifications & Licensure

ID State Medical License 2021 - 2025
OR State Medical License 2003 - 2025
IL State Medical License 1994 - 2005
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Sorafenib, Epirubicin, Ifosfamide, and Radiation Therapy Followed By Surgery in Treating Patients With High-Risk Stage II or Stage III Soft Tissue Sarcoma Start of enrollment: 2009 Feb 01
Completed
Phase 1
S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Start of enrollment: 2011 Apr 01
Active, not recruiting
Phase 3
Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma Start of enrollment: 2012 Apr 01
Completed
Not Applicable
Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma Start of enrollment: 2012 Mar 13
Completed
Phase 2
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery Start of enrollment: 2012 Aug 08
Active, not recruiting
Phase 3
Phase 3 Study to Treat Patients With Soft Tissue Sarcomas Start of enrollment: 2014 Jan 01
Completed
Phase 3
Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma Start of enrollment: 2013 Dec 03
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumors.
Young Kwang Chae, Megan Othus, Sandip Patel, Benjamin Powers, Chung-Tsen Hsueh
Journal for Immunotherapy of Cancer. 2024-09-28
4 citations
SWOG 1609 cohort 48: anti-CTLA-4 and anti-PD-1 for advanced gallbladder cancer.
Sandip P Patel, Elizabeth Guadarrama, Young Kwang Chae, Michael J Dennis, Benjamin C Powers
Cancer. 2024-09-01
1 citations
Adjuvant Everolimus in Non-Clear Cell Renal Cell Carcinoma: A Secondary Analysis of a Randomized Clinical Trial.
Shuchi Gulati, Catherine Tangen, Christopher W Ryan, Ulka N Vaishampayan, Brian M Shuch
JAMA Network Open. 2024-08-01

Press Mentions

Analysis of Human Performance Deficiencies Associated with Surgical Adverse EventsJuly 3rd, 2019
SWOG Launches National Immunotherapy Clinical Trial for Rare CancersJanuary 18th, 2017

Professional Memberships

American Society of Clinical Oncology - ASCO
Member